H.R. 5801 117th Congress
HELP Copays Act
- Health
- Sponsor: Rep. McEachin, A. Donald [D-VA-4]
- Congress.gov ↗
Latest action, Nov 2, 2021: Referred to the Subcommittee on Health.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
62 cosponsors
Sponsored by Rep. McEachin, A. Donald [D-VA-4] (Democrat). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
58 D · 4 R
- Democrat
- Republican
- Independent
Referred to: House: Energy and Commerce Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
ABBVIE INC.
W STRATEGIES, LLC
5 reports
5 reports
ABBVIE, INC.
FEDERAL STREET STRATEGIES, LLC
5 reports
AMERICAN SOCIETY OF HEMATOLOGY
5 reports
5 reports
5 reports
5 reports
5 reports
5 reports
HEMOPHILIA FEDERATION AMERICA
5 reports
5 reports
NATIONAL BLEEDING DISORDER FOUNDATION (FKA NATIONAL HEMOPHILIA FOUNDATION)
ARTEMIS POLICY GROUP LLC
5 reports
5 reports
5 reports
SUSAN G. KOMEN
ARTEMIS POLICY GROUP LLC
5 reports
All 25 of 39 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| ABBVIE INC. | W STRATEGIES, LLC | 5 | $0 | Q4 2021 | Q3 2022 | yes |
| ABBVIE INC. | 5 | $9.5M | Q4 2021 | Q3 2022 | yes | |
| ABBVIE, INC. | FEDERAL STREET STRATEGIES, LLC | 5 | $0 | Q4 2021 | Q3 2022 | yes |
| AMERICAN SOCIETY OF HEMATOLOGY | 5 | $150K | Q4 2021 | Q3 2022 | yes | |
| AMGEN INC | 5 | $12.6M | Q4 2021 | Q3 2022 | yes | |
| ARTHRITIS FOUNDATION | 5 | $375K | Q4 2021 | Q3 2022 | yes | |
| ASSOCIATION FOR CLINICAL ONCOLOGY | 5 | $670K | Q4 2021 | Q3 2022 | yes | |
| GENENTECH INC | 5 | $10.3M | Q4 2021 | Q3 2022 | yes | |
| GSK (FKA GLAXOSMITHKLINE INC.) | 5 | $5.5M | Q4 2021 | Q3 2022 | yes | |
| HEMOPHILIA FEDERATION AMERICA | 5 | $30K | Q4 2021 | Q3 2022 | yes | |
| MERCK & CO INC | 5 | $9.8M | Q4 2021 | Q3 2022 | yes | |
| NATIONAL BLEEDING DISORDER FOUNDATION (FKA NATIONAL HEMOPHILIA FOUNDATION) | ARTEMIS POLICY GROUP LLC | 5 | $254K | Q4 2021 | Q3 2022 | yes |
| NATIONAL MULTIPLE SCLEROSIS SOCIETY | 5 | $247K | Q4 2021 | Q3 2022 | yes | |
| OTSUKA AMERICA PHARMACEUTICAL, INC. | 5 | $1.4M | Q4 2021 | Q3 2022 | yes | |
| SUSAN G. KOMEN | ARTEMIS POLICY GROUP LLC | 5 | $208K | Q4 2021 | Q3 2022 | yes |
| THE HEMOPHILIA ALLIANCE | ARTEMIS POLICY GROUP LLC | 5 | $208K | Q4 2021 | Q3 2022 | yes |
| THE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMEN | 5 | $320K | Q4 2021 | Q3 2022 | yes | |
| TRINITY HEALTH | 5 | $1.0M | Q4 2021 | Q3 2022 | yes | |
| ABBVIE | BROWNSTEIN HYATT FARBER SCHRECK, LLP | 4 | $0 | Q1 2022 | Q3 2022 | yes |
| ABBVIE INC. | OGR | 4 | $0 | Q1 2022 | Q3 2022 | yes |
| AMERICAN COLLEGE OF RHEUMATOLOGY | 4 | $400K | Q1 2022 | Q3 2022 | yes | |
| NATIONAL PSORIASIS FOUNDATION | 4 | $60K | Q1 2022 | Q3 2022 | yes | |
| PATIENT ACCESS NETWORK FOUNDATION | VENABLE LLP | 4 | $120K | Q1 2022 | Q3 2022 | — |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 4 | $28.3M | Q1 2022 | Q3 2022 | yes | |
| THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH | 4 | $200K | Q4 2021 | Q3 2022 | yes |